Cover Image
Market Research Report

Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives

Published by GBI Research Product code 252729
Published Content info 110 Pages
Immediate Delivery Available
Price
Back to Top
Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives
Published: October 15, 2012 Content info: 110 Pages
Description

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives", which provides insights into the antidepressants market until 2018. The report is built using data sourced from our proprietary databases and primary and secondary research, in addition to analysis from our in-house specialized team of experts. The report provides an in-depth analysis of the major antidepressants therapies, including SSRIs, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), covering Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD). The report provides the sales for the global antidepressant market in addition to the individual indication markets. It also examines the global antidepressant market treatment usage patterns, in addition to the geographical distribution of antidepressants across the US, the top five countries of Europe, and Japan. The report also includes insights into the antidepressants R&D product pipeline and explores the competitive landscape, including major players in the antidepressants market. Finally, the report also includes analysis on the Mergers and Acquisitions (M&As) and licensing agreements that took place in antidepressant market.

GBI Research analysis shows that the overall global antidepressant market for the four indications, (MDD, OCD, GAD and PD) was valued at $11.9 billion in 2011, growing from $10.5 billion in 2004 and indicating a Compounded Annual Growth Rate (CAGR) of 1.7%. The market is forecast to reach revenues of approximately $13.4 billion by 2018 for the above mentioned four major indications, increasing at a CAGR of 1.8%. Overall the number of prescriptions for antidepressant has risen, but this has been offset by a number of patent expiries and high generic entry. Drugs currently in development have taken on a new multi-targeted approach, combining targets known to be beneficial for the treatment of MDD, OCD, GAD and PD. The future of the antidepressant market is reliant on the positive safety profiles of drugs in the pipeline, with no disease-modifying therapies expected to enter the market in the near future.

Scope

  • The report analyzes the treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global antidepressant market for MDD, OCD, GAD and PD.
  • Data and analysis on the antidepressant market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
  • Annualized market data for the antidepressant market from 2004 to 2011, with forecasts to 2018.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns (diseased population, diagnosis population and prescription population).
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global antidepressant market including top company benchmarking. The key companies studied in this report are Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Forest laboratories and Lundbeck.
  • Key M&A activities and licensing agreements that took place between 2009 and 2012 in the antidepressants therapeutics market.

Reasons to buy

  • Align their product portfolio to markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Device a more tailored country strategy through the understanding of key drivers and barriers and the market potential of each indication.
  • Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Executive Summary

'Considerable Scope for Improvement' in Antidepressants Market, Says Report

Further research into the disease etiology of a number of mental health disorders would open up considerable scope for improvement in the development of antidepressants, says a new report by GBI Research.

The report* states that the global antidepressants market for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD) - estimated at $11.9 billion in 2011 - is forecast to generate $13.4 billion by 2018. Antidepressants are among the top three most prescribed classes of drugs in the US, along with cholesterol-lowering drugs and painkillers.

The report states that Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) are the most commonly prescribed classes of antidepressants, but many patients fail to respond adequately to them, while a significant number of patients also discontinue therapy due to negative and unwanted side effects.

Latency is also a factor in drug compliance, as the positive effects of antidepressants may only be seen after around six weeks, leading to more instances of treatment discontinuance due to frustration and lost confidence in the drug. The report estimates that around 25% of patients will stop taking their prescribed medication within the first four weeks of treatment.

The pharmaceutical industry has so far struggled to improve on current antidepressants, partly due to inadequate understanding and the difficulty of conducting clinical trials, according to GBI Research analysis. A notably high placebo effect, and a lack of objective assessment criteria and financing all represent drawbacks for scientific study into antidepressant therapeutics.

Without major breakthroughs in scientific understanding, development activity in this therapeutic area will be restricted. However, this does leave considerable scope for improvement over the current treatment options if understanding of the disease etiology improves.

Antidepressants Market to 2018 - Despite Safety Concerns, Selective Serotonin Re-uptake Inhibitors (SSRIs) Continue to Dominate in the Absence of Effective Therapeutic Alternatives

This report provides an in-depth analysis of the major antidepressants therapies, including SSRIs, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), covering Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) and Panic Disorder (PD). It provides the sales, treatment usage patterns for the global antidepressant market in addition to the individual indication markets. It also provides the geographical distribution of antidepressants across the US, the top five countries of Europe, and Japan, and gives insights into the antidepressants R&D product pipeline and explores the competitive landscape, including major players in the antidepressants market. Finally, the report also includes analysis on the Mergers and Acquisitions (M&As) and licensing agreements that took place in antidepressant market.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Antidepressants Market to 2018-Introduction

3. Market Overview

  • 3.1. Introduction
  • 3.2. Classification of Antidepressants
    • 3.2.1. Selective Serotonin Reuptake Inhibitors
    • 3.2.2. Serotonin-Norepinephrine Reuptake Inhibitors
    • 3.2.3. Noradrenergic and Specific Serotonergic Antidepressants
    • 3.2.4. Norepinephrine Reuptake Inhibitors
    • 3.2.5. Norepinephrine-Dopamine Reuptake Inhibitors
    • 3.2.6. Norepinephrine-Dopamine Disinhibitors
    • 3.2.7. Serotonin Antagonist and Reuptake Inhibitors
    • 3.2.8. Tricyclic Antidepressants
    • 3.2.9. Tetracyclic Antidepressants
    • 3.2.10. Monoamine Oxidase Inhibitors
    • 3.2.11. Others
  • 3.3. Adverse Effects
  • 3.4. Major Marketed Products in the Antidepressants Therapy Area
  • 3.5. Future Developments
  • 3.6. Revenue
  • 3.7. Annual Cost of Therapy
  • 3.8. Treatment Usage Patterns
    • 3.8.1. Diseased Population
    • 3.8.2. Diagnosed Population
    • 3.8.3. Prescription Population
  • 3.9. Drivers and Restraints of the Antidepressants Market
    • 3.9.1. Drivers
    • 3.9.2. Restraints

4. Therapeutic Landscape

  • 4.1. Antidepressants Market for Major Depressive Disorder
    • 4.1.1. Introduction
    • 4.1.2. Revenue and Forecasts
    • 4.1.3. Annual Cost of Therapy
    • 4.1.4. Treatment Usage Patterns
    • 4.1.5. Geographical Segmentation
  • 4.2. Drivers and Restraints for the Antidepressants Market for Major Depressive Disorder
    • 4.2.1. Drivers
    • 4.2.2. Restraints
  • 4.3. Antidepressants Market for Obsessive-Compulsive Disorder
    • 4.3.1. Introduction
    • 4.3.2. Revenue and Forecasts
    • 4.3.3. Annual Cost of Therapy
    • 4.3.4. Treatment Usage Patterns
    • 4.3.5. Geographical Segmentation
  • 4.4. Drivers and Restraints for the Antidepressants Market for Obsessive-Compulsive Disorder
    • 4.4.1. Drivers
    • 4.4.2. Restraints
  • 4.5. Antidepressants Market for Generalized Anxiety Disorder
    • 4.5.1. Introduction
    • 4.5.2. Revenue and Forecasts
    • 4.5.3. Annual Cost of Therapy
    • 4.5.4. Treatment Usage Patterns
    • 4.5.5. Geographical Segmentation
  • 4.6. Drivers and Restraints for the Antidepressants Market for Generalized Anxiety Disorder
    • 4.6.1. Drivers
    • 4.6.2. Restraints
  • 4.7. Antidepressants Market for Panic Disorder
    • 4.7.1. Introduction
    • 4.7.2. Revenue and Forecasts
    • 4.7.3. Annual Cost of Therapy
    • 4.7.4. Treatment Usage Patterns
    • 4.7.5. Geographical Segmentation
  • 4.8. Drivers and Restraints for the Antidepressants Market for Panic Disorder
    • 4.8.1. Drivers
    • 4.8.2. Restraints

5. Geographical Landscape

  • 5.1. The US
    • 5.1.1. Revenue and Forecasts
    • 5.1.2. Annual Cost of Therapy
    • 5.1.3. Treatment Usage Patterns
  • 5.2. EU5
    • 5.2.1. Revenue and Forecasts
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Treatment Usage Patterns
  • 5.3. Japan
    • 5.3.1. Revenue and Forecasts
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Treatment Usage Patterns

6. Pipeline Analysis

  • 6.1. Introduction
  • 6.2. Summary of the Current Antidepressants R&D Pipeline
  • 6.3. Profiles of Key Late-Stage Drugs in the Antidepressants Market
    • 6.3.1. Vortioxetine (Lu AA21004)
    • 6.3.2. F-2695(levomilnacipran)
    • 6.3.3. LY-2216684(edivoxetine)
    • 6.3.4. OPC-34712
    • 6.3.5. EB-1010/Amitifadine
    • 6.3.6. PNB01

7. Competitive Landscape

  • 7.1. Competitive Profiling
    • 7.1.1. H. Lundbeck
    • 7.1.2. AstraZeneca
    • 7.1.3. Eli Lilly and Company
    • 7.1.4. Forest Laboratories
    • 7.1.5. Pfizer Inc.
    • 7.1.6. GlaxoSmithKline
    • 7.1.7. Bristol-Myers Squibb Company

8. Strategic Consolidations

  • 8.1. Merger and Acquisition Deals
    • 8.1.1. Paladin Labs Completes Acquisition of Labopharm
    • 8.1.2. High River Acquires 6.5% Stake in Forest Laboratories
    • 8.1.3. Forest Laboratories Completes Acquisition of Clinical Data
    • 8.1.4. Azur Pharma Completes Merger with Jazz Pharmaceuticals in All Stock Transaction
    • 8.1.5. Nuvo Research Acquires ZARS Pharma
    • 8.1.6. Sun Pharmaceutical Acquires Remaining 24% Stake of Caraco Pharmaceutical
  • 8.2. Licensing Agreements
    • 8.2.1. Labopharm Enters into Licensing Agreement with Angelini Group for OLEPTRO
    • 8.2.2. Omeros Expands Licensing Agreement with Daiichi Sankyo
    • 8.2.3. Jazz Pharmaceuticals Enters into Sub-Licensing Agreement with Anchen
    • 8.2.4. AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept
    • 8.2.5. Indevus Pharmaceuticals Enters into Licensing Agreement with Teva Pharmaceutical
    • 8.2.6. Impax Laboratories Enters into Licensing Agreement with Wyeth
    • 8.2.7. Mylan Enters into Licensing Agreement with GlaxoSmithKline
    • 8.2.8. Tikvah Therapeutics Signs Licensing Agreement with Therapade Technologies
    • 8.2.9. GlaxoSmithKline Signs an Agreement with Fabre-Kramer Pharmaceuticals
    • 8.2.10. Jazz Pharmaceuticals Enters into Licensing Agreement with Solvay
    • 8.2.11. Targacept Enters into Licensing Agreement with Yale University
  • 8.3. Co-Development Deals
    • 8.3.1. Lundbeck Enters into Co-Development Agreement with Otsuka Pharmaceutical
    • 8.3.2. Eli Lilly Terminates Co-Development Agreement with Boehringer Ingelheim
    • 8.3.3. Lundbeck Enters into Co-Development Agreement with Takeda

9. Appendix

  • 9.1. Market Definitions
  • 9.2. Abbreviations
  • 9.3. Sources
  • 9.4. Research Methodology
    • 9.4.1. Coverage
    • 9.4.2. Secondary Research
    • 9.4.3. Primary Research
  • 9.5. Therapeutic Landscape
    • 9.5.1. Epidemiology-based Forecasting
    • 9.5.2. Market Size by Geography
  • 9.6. Geographical Landscape
  • 9.7. Pipeline Analysis
  • 9.8. Competitive Landscape
    • 9.8.1. Expert Panel Validation
  • 9.9. Contact Us
  • 9.10. Disclaimer

List of Tables

  • Table 1: Global Antidepressants Market, Marketed Products, 2012
  • Table 2: Antidepressants Market, Global, Revenue ($bn), 2004-2011
  • Table 3: Antidepressants Market, Global, Revenue Forecast ($bn), 2011-2018
  • Table 4: Antidepressants Market, Global, Annual Cost of Therapy ($), 2004-2011
  • Table 5: Antidepressants Market, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 6: Antidepressants Market, Global, Treatment Usage Patterns (millions), 2004-2011
  • Table 7: Antidepressants Market, Global, Treatment Usage Patterns (millions), 2011-2018
  • Table 8: Antidepressants Market, MDD, Global, Revenue ($bn), 2004-2011
  • Table 9: Antidepressants Market, MDD, Global, Revenue Forecast ($bn), 2011-2018
  • Table 10: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2004-2011
  • Table 11: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 12: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2004-2011
  • Table 13: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2011-2018
  • Table 14: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2004-2011
  • Table 15: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2011-2018
  • Table 16: Common Obsessions and Compulsions in Obsessive-Compulsive Disorder
  • Table 17: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue ($bn), 2004-2011
  • Table 18: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue Forecast ($bn), 2011-2018
  • Table 19: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2004-2011
  • Table 20: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 21: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2004-2011
  • Table 22: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2011-2018
  • Table 23: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2004-2011
  • Table 24: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2011-2018
  • Table 25: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue ($bn), 2004-2011
  • Table 26: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue Forecast ($bn), 2011-2018
  • Table 27: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2004-2011
  • Table 28: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 29: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2004-2011
  • Table 30: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2011-2018
  • Table 31: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2004-2011
  • Table 32: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2011-2018
  • Table 33: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2004-2011
  • Table 34: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2011-2018
  • Table 35: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2004-2011
  • Table 36: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2011-2018
  • Table 37: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2004-2011
  • Table 38: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2011-2018
  • Table 39: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2004-2011
  • Table 40: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2011-2018
  • Table 41: Antidepressants Market, Global, Revenues by Geography ($bn), 2004-2011
  • Table 42: Antidepressants Market, Global, Revenues by Geography ($bn), 2011-2018
  • Table 43: Antidepressants Market, The US, Revenue ($bn), 2004-2011
  • Table 44: Antidepressants Market, The US, Revenue Forecast ($bn), 2011-2018
  • Table 45: Antidepressants Market, The US, Annual Cost of Therapy ($), 2004-2011
  • Table 46: Antidepressants Market, The US, Annual Cost of Therapy ($), 2011-2018
  • Table 47: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2004-2011
  • Table 48: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2011-2018
  • Table 49: Antidepressants Market, EU5, Revenue ($bn), 2004-2011
  • Table 50: Antidepressants Market, EU5, Revenue Forecast ($bn), 2011-2018
  • Table 51: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2004-2011
  • Table 52: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2011-2018
  • Table 53: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2004-2011
  • Table 54: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2011-2018
  • Table 55: Antidepressants Market, Japan, Revenue ($m), 2004-2011
  • Table 56: Antidepressants Market, Japan, Revenue ($m), 2011-2018
  • Table 57: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2004-2011
  • Table 58: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2011-2018
  • Table 59: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2004-2011
  • Table 60: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2011-2018
  • Table 61: Antidepressants Market, Pipeline, 2012
  • Table 62: Lundbeck, Antidepressant Pipeline Products, 2011
  • Table 63: AstraZeneca, Antidepressants Pipeline, 2011
  • Table 64: Eli Lilly and Company, Antidepressants Pipeline, 2011
  • Table 65: Forest Laboratories, MDD, Pipeline Products, 2011

List of Figures

  • Figure 1: Antidepressants Market, Global, Revenue ($bn), 2004-2018
  • Figure 2: Antidepressants Market, Global, Annual Cost of Therapy ($), 2004-2018
  • Figure 3: Antidepressants Market, Global, Therapeutic Usage Patterns (millions), 2004-2018
  • Figure 4: Antidepressants Market, MDD, Global, Revenue ($bn), 2004-2018
  • Figure 5: Antidepressants Market, MDD, Global, Annual Cost of Therapy ($), 2004-2018
  • Figure 6: Antidepressants Market, MDD, Global, Treatment Usage Patterns (millions), 2004-2018
  • Figure 7: Antidepressants Market, MDD, Global, Market Segmentation by Geography ($bn), 2004-2018
  • Figure 8: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Revenue ($bn), 2004-2018
  • Figure 9: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Annual Cost of Therapy ($), 2004-2018
  • Figure 10: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Treatment Usage Patterns (millions), 2004-2018
  • Figure 11: Antidepressants Market, Obsessive-Compulsive Disorder, Global, Market Segmentation by Geography ($m), 2004-2018
  • Figure 12: Antidepressants Market, Generalized Anxiety Disorder, Global, Revenue ($bn), 2004-2018
  • Figure 13: Antidepressants Market, Generalized Anxiety Disorder, Global, Annual Cost of Therapy ($), 2004-2018
  • Figure 14: Antidepressants Market, Generalized Anxiety Disorder, Global, Treatment Usage Patterns (millions), 2004-2018
  • Figure 15: Antidepressants Market, Generalized Anxiety Disorder, Global, Market Segmentation by Geography ($m), 2004-2018
  • Figure 16: Antidepressants Market, Panic Disorder, Global, Revenue ($m), 2004-2018
  • Figure 17: Antidepressants Market, Panic Disorder, Global, Annual Cost of Therapy ($), 2004-2018
  • Figure 18: Antidepressants Market, Panic Disorder, Global, Treatment Usage Patterns (millions), 2004-2018
  • Figure 19: Antidepressants Market, Panic Disorder, Global, Market Segmentation by Geography ($m), 2004-2018
  • Figure 20: Antidepressants Market, Global, Revenues by Geography ($bn), 2004-2018
  • Figure 21: Antidepressants Market, The US, Revenue ($bn), 2004-2018
  • Figure 22: Antidepressants Market, The US, Annual Cost of Therapy ($), 2004-2018
  • Figure 23: Antidepressants Market, The US, Treatment Usage Patterns (millions), 2004-2018
  • Figure 24: Antidepressants Market, EU5, Revenue ($bn), 2004-2018
  • Figure 25: Antidepressants Market, EU5, Annual Cost of Therapy ($), 2004-2018
  • Figure 26: Antidepressants Market, EU5, Treatment Usage Patterns (millions), 2004-2018
  • Figure 27: Antidepressants Market, Japan, Revenue ($m), 2004-2018
  • Figure 28: Antidepressants Market, Japan, Annual Cost of Therapy ($), 2004-2018
  • Figure 29: Antidepressants Market, Japan, Treatment Usage Patterns (millions), 2004-2018
  • Figure 30: Antidepressants Market, SWOT Analysis, Lundbeck, 2011
  • Figure 31: Antidepressants Market, SWOT Analysis, AstraZeneca, 2011
  • Figure 32: Antidepressants Market, SWOT Analysis, Eli Lilly and Company, 2011
  • Figure 33: Antidepressants Market, SWOT Analysis, Forest Laboratories, 2011
  • Figure 34: Antidepressants Market, SWOT Analysis, Pfizer Inc., 2011
  • Figure 35: Antidepressants Market, SWOT Analysis, GlaxoSmithKline, 2011
  • Figure 36: Antidepressants Market, SWOT Analysis, Bristol-Myers Squibb, 2011
  • Figure 37: GBI Research Market Forecasting Model
Back to Top